ACH NYSE Earnings call
Accendra Health Inc/va/ (ACH) · Q2 2026 results
Share price: $0.15 · 2026-11-11
Results Q2 2026 vs Q1 2026 · previous quarter · published 10 Aug 2026 and 11 May 2026
Net loss widened on the previous quarter. Management sounded about as positive as a typical company call, in its script and in answers to analysts.
Only a basic analysis is available for this company at the moment.
1 · Numbers
Loss widened
Net income vs Q1 2026
Net income -89.1M vs -6.5M
Revenue −2.3%
Net income -89.1M vs -869.1M in Q2 2025 and -6.5M last quarter.
2 · How management spoke
Typical
Less upbeat than 61% of company calls
Answers to analysts: typical, in line with the script.
Similar to last call.
3 · What stood out
Figure
Total debt of $1.72 billion decreased by almost $400 following a balance sheet optimization transaction, which impacts the company's financial…
Valuation
Reverse DCF. Free cash flow from the last full fiscal year, grown for 10 years, discounted back, plus a terminal value. “Implied growth” is the rate the current price assumes.
Valuation unavailable: inputs look inconsistent (market value only 0.1x the fcf avg 3y: another reporting currency or a one-off gain).
Current price
$0.15
close of 2026-11-11
Revenue growth, 3 years
−34.8% a year
compound annual rate (CAGR)
Free cash flow 2023
$0.6B
Free cash flow 2024
−$0.0B
Free cash flow 2025
−$0.3B
Read between the lines
-
Key theme
The company began an NOL rights plan while wrapping up a balance sheet optimization transaction to determine what other actions should be taken during the process.
Source quote
“One, as we were wrapping up the balance sheet optimization transaction, we asked ourselves and outside advisers, what else should we be doing at the same time... Mike, there were 2 real drivers that really answers the question of why now. And an NOL rights plan, which I wasn't familiar with, came to our attention and to -- we were educated about.”
-
Dropped
Management plans to educate patients on the pharmacy option because empirical data is starting to show differences in outcomes when patients use the DME channel instead.
Source quote
“Now we're starting to get some empirical data that shows that when a patient uses the DME channel versus the pharmacy... Let me talk a little bit more detail about DME versus pharmacy, -- so the pharmacy option has been in place for several years now. I think that is an opportunity for us to make sure that we're educating patients.”
Tone
How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q2 2026. Ring: Q1 2026.
Script and answers carried a similar tone, so the script's message held up under questioning.
Sentences that drove the tone
“The operational actions underway, the commercial opportunities we have secured and the investments we are making today give us the confidence in our ability to improve execution, accelerate growth and...”
“That improved execution will help us accelerate growth and continue to expand profitability over time.”
“Diabetes grew 4%, which was a 500 basis point improvement in the year-over-year growth rate compared to Q1.”
Full figures
USD · SEC EDGAR XBRL (10-Q, period end 2026-06-30)
| Metric | Q2 2026period end 2026-06-30 | Q1 2026period end 2026-03-31 | Change | Q2 2025 | YoY |
|---|---|---|---|---|---|
| Revenue | 613.2M | 627.8M | −2.3% | 681.9M | −10.1% |
| Gross profit | 263.4M | 278.0M | −5.3% | 324.6M | −18.9% |
| Operating income | -35.1M | 17.1M | Turned loss | -39.7M | Loss narrowed |
| Net income | -89.1M | -6.5M | Loss widened | -869.1M | Loss narrowed |
| EPS | -1.16 | -0.08 | Loss widened | -11.30 | Loss narrowed |
| P/E | 12-mo loss | 12-mo loss | — | 12-mo loss | — |
Topics
Most discussed now
- New With these important milestones largely behind us, I believe the company is well positioned for its next chapter.
- When Accendra Health Inc/va/ went back and did a very high-level kind of Section 382 study, it saw that it has well...
- I am confident and committed that Accendra Health Inc/va/ will have a successful CEO transition.
- The other aspect of it is Accendra Health Inc/va/ is continuing to do things to streamline its operations in sleep focused primarily with...
- What was unusual is a couple of months ago, Accendra Health Inc/va/ started seeing the actual not number of audits, the number...
Faded since Q1 2026
- Dropped I would certainly caution everybody on relying too much on those.
- Fading The sleep business, absent, the large commercial payor change grew very nicely as well.
- Dropped With Accendra Health Inc/va/'s team ensuring continuity of care for the patients, while also minimizing its cost to transition the business.
- Fading To secure this smooth transition for patients, Accendra Health Inc/va/ engages with another industry player to sell them the substantial…
Latest announcements
Official filings, newest first.
- Director or officer change; Regulation FD disclosure; Other events · SEC 8-K
- Regulation FD disclosure · SEC 8-K
- Material agreement; Change to shareholder rights; Articles or bylaws amended; Regulation FD disclosure · SEC 8-K
- Results of operations; Regulation FD disclosure · SEC 8-K
- Director or officer change; Regulation FD disclosure · SEC 8-K
- Other events · SEC 8-K
- Material agreement; New financial obligation; Other events · SEC 8-K
- Regulation FD disclosure · SEC 8-K